Glycyrrhetinic Acid/Telmesteine/Vitis Vinifera Extract(Glycyrrhetinic Acid/Telmesteine/Vitis Vinifera Extract) - 药物靶点：11β-HSD1_在研适应症：特应性皮炎，湿疹_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Atopiclair、Zarzenda

靶点

11β-HSD1

作用机制

11β-HSD1抑制剂(11β-羟基类固醇脱氢酶-1抑制剂)

治疗领域

免疫系统疾病遗传病与畸形皮肤和肌肉骨骼疾病

在研适应症

特应性皮炎湿疹

非在研适应症-

原研机构

Intendis GmbH

在研机构

Intendis GmbH

非在研机构-

最高研发阶段批准上市

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

结构

分子式C7H11NO4S

InChIKeyXBJWOGLKABXFJE-YFKPBYRVSA-N

CAS号122946-43-4

查看全部结构式(2)

关联

2

项与 Glycyrrhetinic Acid/Telmesteine/Vitis Vinifera Extract 相关的临床试验

EUCTR2007-002133-36-ES / Not yet recruiting临床4期

A multicenter, randomized, double-blind clinical study to examine the efficacy and safety of Zarzenda® in comparison to Elidel® in the management of mild to moderate atopic dermatitis in children and adolescents.Estudio clínico multicéntrico, aleatorizado y en doble ciego para examinar la eficacia y la seguridad de Zarzenda® en comparación con Elidel® en el tratamiento de la dermatitis atópica leve a moderada en niños y adolescentes.

开始日期2008-02-05

申办/合作机构

Intendis GmbH

EUCTR2007-002133-36-IT / Not yet recruitingN/A

A multicenter, randomised, double-blind clinical study to examine the efficacy and safety of ZARZENDA in comparison to Elidel in the management of mild to moderate Atopic Dermatitis in children and adolescents. - ND

开始日期2008-01-31

申办/合作机构

Intendis GmbH

100 项与 Glycyrrhetinic Acid/Telmesteine/Vitis Vinifera Extract 相关的临床结果

登录后查看更多信息

100 项与 Glycyrrhetinic Acid/Telmesteine/Vitis Vinifera Extract 相关的转化医学

登录后查看更多信息

100 项与 Glycyrrhetinic Acid/Telmesteine/Vitis Vinifera Extract 相关的专利（医药）

登录后查看更多信息

14

项与 Glycyrrhetinic Acid/Telmesteine/Vitis Vinifera Extract 相关的文献（医药）

2023-01-01·Anti-inflammatory & anti-allergy agents in medicinal chemistry

A New Moisturiser Improves DNCB-induced Atopic Dermatitis-like Symptoms and Restores Skin Barrier Function in BALB/c Mice.

Article

作者: Phuong Vu, Thao Thi ; Foucher, Christelle ; Guy, Martine ; Anh Tran, Tu Nguyen ; Bisson, Jean-François ; Colin, Julie ; Hidalgo, Sophie ; Nguyen, Hao Trong

INTRODUCTIONAtopic dermatitis (AD) is a chronic, inflammatory skin disorder with eczematous and pruritic lesions. Topical moisturisers and either topical corticosteroids or calcineurin inhibitors are usually recommended. Restoring the skin barrier function alleviates AD symptoms.OBJECTIVETo evaluate the efficacy of a new moisturiser compared to commercially available products in an AD murine model.METHODSExperimental AD was induced with topical applications of 2,4-DiNitroChloroBenzene (DNCB) on the shaved back skin of BALB/c mice from Day 1 to Day 38. Mice were randomized to either Vehicle/-, DNCB/-, or DNCB/Eczekalm (test product), DNCB/Atopiclair®, or DNCB/Lipikar (reference products) groups. Once daily application of either Eczekalm or Atopiclair® or Lipikar on the AD lesion was performed from Day 32 to Day 38. The AD severity index (ADSI) and animal behaviour were monitored throughout the study. The trans-epidermal water loss (TEWL) was measured on the sacrifice day (Day 39).RESULTSAt Day39, ADSI in the DNCB/Eczekalm, DNCB/Lipikar, and DNCB/Atopiclair® groups were significantly lower by -70%, -68%, and -57%, respectively, as compared to DNCB/- (p < 0.001). No sign of erythema was observed in the DNCB/Eczekalm group. Mean scores of skin oedema, excoriation, and dryness in the DNCB/Eczekalm, DNCB/Lipikar, and DNCB/Atopiclair® groups were significantly lower than in the DNCB/-. No significant difference was observed between DNCB/Eczekalm and DNCB/Lipikar groups. Mean TEWL in DNCB/Eczekalm group was significantly lower than the ones of DNCB/Atopiclair® (-43%, p < 0.001) and DNCB/Lipikar (-15%, p < 0.05).CONCLUSIONEczekalm treatment significantly reduced the inflammatory effects due to AD and itching episodes and restored the skin barrier function.

2019-06-01·Clinical and Experimental Dermatology4区 · 医学

What's new in atopic eczema? An analysis of systematic reviews published in 2016. Part 1: treatment and prevention

4区 · 医学

Review

作者: Thomas, K. S. ; Lloyd‐Lavery, A. ; Grindlay, D. J. C. ; Harman, K. E. ; Solman, L. ; Rogers, N. K.

This review is part of a series of annual updates summarizing the evidence base for atopic eczema (AE). It provides a summary of key findings from 28 systematic reviews that were published or indexed during 2016 with a focus on treatment and prevention of AE. There is reasonable evidence of benefit for topical corticosteroids, calcineurin inhibitors, a glycyrrhetinic acid-containing preparation (Atopiclair^® ), oral ciclosporin, oral azathioprine, narrowband ultraviolet B radiation and education programmes. Overall, there is evidence that topical corticosteroids and calcineurin inhibitors have similar efficacy and that both can prevent AE flares when used twice weekly as maintenance therapy. However, topical calcineurin inhibitors are costlier and have more adverse reactions, thus topical corticosteroids should remain the standard of care for patients with AE. There is no evidence that multiple applications are better than once-daily application of topical corticosteroid. There is inconsistent evidence to support omalizumab and specific allergen immunotherapy use in AE. There is some evidence that vitamin D supplementation and synbiotics reduce AE severity, although the margin of improvement may not be clinically meaningful. There is little evidence to support the use of wet wraps or of complementary/alternative medicine (including Chinese herbal medicine). There is some evidence to suggest that a diet high in fish in infancy may be preventative for AE, but other dietary interventions for the prevention of AE show little promise. This review provides a succinct guide for clinicians and patients wishing to remain up to date with the latest evidence for the treatment and prevention of AE.

2017-04-01·British Journal of Dermatology1区 · 医学

What is the evidence base for atopic eczema treatments? A summary of published randomized controlled trials

1区 · 医学

Review

作者: Smith, S. ; Rogers, N.K. ; Delamere, F.M. ; Barbarot, S. ; Thomas, K.S. ; Nankervis, H. ; Williams, H.C.

Atopic eczema (AE) is a common chronic inflammatory skin condition. While many AE treatment options are available, the evidence to support their efficacy varies in depth and quality. In 2000, a National Institute for Health Research (NIHR) Health Technology Assessment systematic review identified and evaluated existing randomized controlled trials (RCTs) of AE treatments. To ensure continuing utility, the NIHR commissioned an update to the review. Here, we present an overview of the updated report and its key findings. Systematic reviews and RCTs of AE treatments that included participants with AE (criteria based or diagnosed) were identified using Medline, Embase, CENTRAL, Latin American and Caribbean Health Sciences, Allied and Complementary Medicine Database, Cumulative Index to Nursing and Allied Health Literature and Cochrane Skin Group Specialised Register [searched to 31 August 2013 (RCTs) and 31 December 2015 (systematic reviews)]. Outcome measures included symptoms, AE severity, quality of life and adverse effects. Study quality was assessed using the Cochrane Collaboration risk of bias tool. Of the 287 new RCTs identified, only 22 (8%) were judged to have a low risk of bias. When combined with RCTs from the previous review (n = 254), we found 'reasonable evidence of benefit' for corticosteroids, calcineurin inhibitors, Atopiclair^® , ciclosporin, azathioprine, ultraviolet radiation and education programmes. Interventions with reasonable evidence of 'no benefit' included some dietary interventions, ion exchange water softeners, multiple daily applications of topical corticosteroids and antibiotic-containing corticosteroids for noninfected AE. Many common treatments lack evidence of efficacy and warrant further evaluation. The evidence base for AE is still hampered by poor trial design and reporting. The trials included in this review were used to establish the Global Resource of EczemA Trials (GREAT) database.

100 项与 Glycyrrhetinic Acid/Telmesteine/Vitis Vinifera Extract 相关的药物交易

登录后查看更多信息